Clinical trial
Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to…
NCT00324649 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00324649 |
|---|---|
| Title | Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada |
| Official title | Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). |
| Acronym | RECOMB |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV-1 |
| Intervention type | Drug |
| Interventions | Truvada, Zidovudine/lamivudine |
| Enrollment | 80 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 11, 2006 |
| Last update posted | Aug 17, 2015 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: